Molecular Markers in Testicular Germ Cell Tumors – Objects of Clinical Research or Close to Becoming Clinical Tools?

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Oncology Research and Treatment

• Publication date

  2001-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000050302PMID 11441294
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation

  2000cited by this paper
• Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours

  2000cited by this paper
• Molecular Genetic Parameters in Pathogenesis and Prognosis of Testicular Germ Cell Tumors

  2000cited by this paper
• Genetics and biology of adult human male germ cell tumors.

  2000cited by this paper
• Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer.

  2000cited by this paper
• mdm-2 expression in human testicular germ-cell tumors and its clinical value.

  1999cited by this paper
• Detection and clinical importance of micrometastatic disease.

  1999cited by this paper
• Telomerase activity distinguishes between neuroblastomas with good and poor prognosis.

  1999cited by this paper
• Risk factors for relapse in stage I non‐seminomatous germ‐cell tumors: Preliminary results of the German multicenter trial

  1999cited by this paper
• Telomerase activity distinguishes between neuroblastomas with poor prognosis

  1999cited by this paper
• Susceptibility to testicular germ-cell tumours in a 129.MOLF-Chr 19 chromosome substitution strain

  1999cited by this paper
• Telomerase activity in germ cell cancers and mature teratomas.

  1999cited by this paper
• High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor.

  1999cited by this paper
• Late effects of treatment for germ cell tumors during childhood and adolescence.

  1999cited by this paper
• Treatment of testicular tumours based on risk factors.

  1999cited by this paper
• Detection of circulating testicular cancer cells in peripheral blood.

  1999cited by this paper
• Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas.

  1999cited by this paper
• Distinct p53‐independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines

  1999cited by this paper
• The complexity of p53 modulation: emerging patterns from divergent signals.

  1998cited by this paper
• A new human nm23 homologue (nm23‐H5) specifically expressed in testis germinal cells 1

  1998cited by this paper
• The MDM2 gene amplification database.

  1998cited by this paper
• Detection of tumor cells in peripheral blood samples from patients with germ cell tumors using immunocytochemical and reverse transcriptase-polymerase chain reaction techniques

  1998cited by this paper
• Detection and characterization of carcinoma cells in the blood.

  1998cited by this paper
• Poor prognosis germ cell tumors: current status and future directions.

  1998cited by this paper
• Candidate regions for testicular cancer susceptibility genes. The International Testicular Cancer Linkage Consortium.

  1998cited by this paper
• Poor prognosis germ cell tumors: current status and future directions.

  1998cited by this paper
• Candidate regions for testicular cancer susceptibility genes

  1998cited by this paper
• Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl‐2 oncogene in primary testicular germ cell tumours

  1998cited by this paper
• Detection of germ cell tumor cells in apheresis products using polymerase chain reaction.

  1998cited by this paper
• A genetic perspective of male germ cell tumors.

  1998cited by this paper
• MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis.

  1998cited by this paper
• Detection of chromosomal aberrations in seminomatous germ cell tumours using comparative genomic hybridization

  1997cited by this paper
• Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR.

  1997cited by this paper
• Risk of second malignant neoplasms among long-term survivors of testicular cancer.

  1997cited by this paper
• Inhibition of telomerase activity by cisplatin in human testicular cancer cells.

  1997cited by this paper
• Testicular germ-cell cancer.

  1997cited by this paper
• Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.

  1997cited by this paper
• Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis

  1996cited by this paper
• Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases.

  1996cited by this paper
• Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.

  1996cited by this paper
• Loss of heterozygosity of tumor suppressor genes in testis cancer.

  1995cited by this paper
• Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors.

  1995cited by this paper
• The p53 and mdm‐2 genes in human testicular germ‐cell tumors

  1995cited by this paper
• Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7).

  1995cited by this paper
• Candidate regions for a testicular cancer susceptibility gene

  1995cited by this paper
• Intracranial Germ Cell Tumors: Detection of p53 Gene Mutations by Single‐strand Conformation Polymorphism Analysis

  1995cited by this paper
• Mutations of the p53 gene are not detectable in human testicular tumors.

  1994cited by this paper
• Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors.

  1994cited by this paper
• Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors.

  1994cited by this paper
• The correlation of P53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis.

  1994cited by this paper
• Allelic loss and somatic differentiation in human male germ cell tumors.

  1994cited by this paper
• Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease.

  1994cited by this paper
• Loss of heterozygosity and decreased expression of NME genes correlate with teratomatous differentiation in human male germ cell tumors.

  1994cited by this paper
• Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.

  1994cited by this paper
• Cytogenetics of male germ-cell tumors.

  1993cited by this paper
• Molecular cytogenetic analysis of i(12p)‐negative human male germ cell tumors

  1993cited by this paper
• Mutations of the p53 gene do not occur in testis cancer.

  1993cited by this paper
• Seminoma of the testis: long-term beneficial and deleterious results of radiation.

  1992cited by this paper
• Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction.

  1991cited by this paper
• Correlation between retinoblastoma gene expression and differentiation in human testicular tumors.

  1991cited by this paper
• Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance.

  1991cited by this paper
• Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies.

  1991cited by this paper
• Cytogenetic and molecular analysis of human male germ cell tumors: Chromosome 12 abnormalities and gene amplification

  1990cited by this paper
• Chromosomal changes in human primary testicular nonseminomatous germ cell tumors.

  1989cited by this paper
• Isochromosome of Chromosome 12: Clinically Useful Marker for Male Germ Cell Tumors

  1989cited by this paper
• Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors.

  1989cited by this paper
• Immunohistological determination of proliferative activity in seminomas.

  1988cited by this paper
• i(12p): specific chromosomal marker in seminoma and malignant teratoma of the testis?

  1983cited by this paper
• Specific chromosome change, i(12p), in testicular tumours?

  1982cited by this paper
• Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

  1977cited by this paper

• Tumor Risk in Disorders of Sex Development

  2010cites this paper
• Der Stellenwert der Targeted-Therapie beim Hodentumor

  2008cites this paper
• [Value of targeted treatment for testicular cancer: from molecular approaches to clinical possibilities].

  2008cites this paper
• Tumor risk in disorders of sex development (DSD).

  2007cites this paper
• Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues.

  2002cites this paper
• Band 24, Heft 1, Februar 2001

  2001cites this paper